Veyonda Awarded First Allowed Patent Application

Noxopharm Limited. ABN 50 608 966 123 Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA 17 March 2020 Sydney, Australia Veyonda® Awarded First Allowed Patent Application Highlights • Australian Patent Office awards allowance on Veyonda® patent application • Important step in securing IP protection over commercial opportunity • Patent term through until July 2036 Sydney, 17 March 2020: Noxopharm (NOX:ASX) announces that Australian patent application No. 2016401508 has been allowed by the Australian Patent Office. The patent claims are directed to a suppository formulation including idronoxil and the allowed claims provide broad coverage for Veyonda® as a therapeutic. Graham Kelly, Noxopharm CEO, said, “This news is an important step forward for the Company and will go a long way to underpinning our proprietary ownership of Veyonda® and what we see as its considerable potential commercial value given the strength of the emerging clinical data.” “To date we have lodge d 5 families of patents, with a 6 th family currently being prepared, all part of an aggressive strategy of building as many patent fences as possible around Veyonda® in major drug territories. The patent allowance announced today is for the very first family and is the most fundamental patent application we have lodged. Collectively, all 6 families are designed to build a substantial IP portfolio around the clinical use of Veyonda®. This portfolio will play an important part of anticipated future partnership negotiations.” This patent application is also being pursued in the United States, Europe, Japan, China, Canada, India, Israel, South Korea, New Zealand, Russia, Singapore and Hong Kong. About Veyonda® Veyonda® is a suppository dosage form of idronoxil, a first -in-class inhibitor of sphingosine -1-phosphate (S1P). S1P is a key secondary messenger in cells, with dual roles of activating major pro -survival signalling pathways and regulating immune cell trafficking i n tissues. Many solid cancers over -express S1P, supporting Noxopharm Limited. ABN 50 608 966 123 Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA unregulated tumour growth and suppressing immune cell populations in tumours. By inhibiting th e over- expression of S1P -driven pro-survival pathways, idronoxil is designed to sensitise cancer cells to the anti - cancer effects of drugs such as doxorubicin , as well as to radiation . By inhibiting the over-expression of S1P- driven exclusion of immune cells from tissues, idronoxi l is designed to restore normal trafficking of immune cells. About Noxopharm Noxopharm is a clinical -stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in the non-oncology drug development company, Nyrada Inc. (ASX:NYR). www.noxopharm.com Investor & Corporate enquiries: Company Secretary: Prue Kelly David Franks M: 0459 022 445 T: +61 2 8072 1400 E: [email protected] E: [email protected] Media enquiries: Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: [email protected] Graham Kelly, CEO and Chairman of Noxopharm, has approved the release of this document to the market. Forward Looking Statements This announcement may contain forward -looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “b elieve”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward -looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward -looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statement.

The release as fetched from its publisher. noxopharm.com ↗